Anne Marie Simon Barfoed

At AbolerIS Pharma, it’s all about creating balance. The Belgian/French biotech company is gearing up for clinical trials of a novel therapy for stabilizing chaotic immune systems. As CEO Ann Meulemans explains, it requires finding the right interplay between management’s industry experience and passion, cutting-edge science from company foun ...

Financing round led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital. AbolerIS is developing a first-in-class drug inducing an immune tolerance-based mechanism that acts upstream of current anti-inflammatory standard of care drugs in autoimmune diseases such as rheumatoid arthritis. Proceeds will be ...

25 July 2023 Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage bioph ...

Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with a Profile that Strongly Supports Further Clinical Development Efforts AX-158 is Being Developed for Once Daily Oral Dosing to Address Autoimmune Diseases by Providing Immunomodulation without Immunosuppression Cambridge, Mass., June 1, 2023 – Artax ...

ARTHEx Biotech is entering a new phase in its development of breakthrough treatments for genetically-driven disorders. It’s set to begin the first clinical trials for one of its microRNA modulators as a therapeutic approach for the degenerative muscular disease myotonic dystrophy type 1.[1]  Yet according to Dr. Frédéric Legros, the company’s ...

Leiden, The Netherlands, 25 May 2023 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round. The round was led by Sound Bioventures whilst the European Innovation Council (EIC) Fund ...

Casper Breum says he can usually tell early on if a startup will be a good fit for investment. As a founding partner at Sound Bioventures, Breum is involved in reviewing the roughly six hundred investor pitches from biotech companies the firm evaluates each year. His predictive ability was honed throughout his career, which he […]

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM1, is expected to initiate in 2H2023 Round led by Columbus Venture Partners, with participation of European Innovation Council (EIC), Hadean Ventures, Sound ...

“We are thrilled to welcome Peter as CSO. His extensive experience in ophthalmology drug development will be invaluable as we advance our lead compound through clinical development. Gabriela’s appointment to the Board brings significant industry and development experience which will be instrumental as we build a pipeline of novel oral therapies for ...

Anne Marie Simon prefers to be backstage. There, from behind the scenes, she’s fearlessly dedicated to helping others shine. In her role as Office Manager for Sound Bioventures, for example, Simon is essential in optimizing the firm’s processes and supporting the investment team. From an early age, Simon knew she had a knack for working […] ...

Teitur Trophics is breaking new ground when it comes to neurodegenerative diseases. After identifying a previously unknown means of preserving functioning brain cells, the biotech company’s founders aim to translate that discovery into therapies for conditions with almost no current treatment options. According to Co-Founder and CEO Simon Mølgaard, ...

Even though it’s based on venom from one of the deadliest snakes in the world, the lead product of biotech startup VarmX can be life-saving for patients on blood thinners. It’s an unexpected turn, but those are the norm for the Dutch company’s Chairman and CEO, Dr. Jan Öhrström. His CV runs the gamut from […]